Prostate Cancer Trial, Recruiting (NCT05109910)

Prostate Cancer Trial, Recruiting NCT05109910 Sponsor: The Netherlands Cancer Institute Condition: Prostate Cancer

Printed from Voxsanity (voxsanity.com.au) — NCT05109910 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Prostate Cancer

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

People who are male and aged 18 years or older
People who have prostate cancer with a calculated risk (using a tool called the Briganti nomogram) of cancer spreading to the lymph nodes of between 5% and 20%, and whose pre-surgery scan (called a PSMA PET/CT) shows no signs of cancer having spread
People who are scheduled to have their prostate removed using a keyhole or robot-assisted surgical procedure
People who have given written consent to take part

Who may not be able to join:

People who have been rated as having very high anaesthetic risk (classified as ASA grade higher than 3) by their medical team
People for whom lymph node removal surgery is not medically suitable
People who have received hormone therapy before surgery (known as neoadjuvant hormone deprivation therapy)
People who have not given consent, or who have withdrawn their consent to participate
People whose pre-surgery PSMA PET/CT scan shows evidence that the cancer has already spread

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 6 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Henk G van der Poel, Prof, The Netherlands Cancer Institute

Phone: 0205129111

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT05109910

Sponsor: The Netherlands Cancer Institute

Phase: Not Applicable

Status: Recruiting

Condition: Prostate Cancer

Trial contact: 0205129111

More information: https://clinicaltrials.gov/study/NCT05109910

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

People who are male and aged 18 years or older
People who have prostate cancer with a calculated risk (using a tool called the Briganti nomogram) of cancer spreading to the lymph nodes of between 5% and 20%, and whose pre-surgery scan (called a PSMA PET/CT) shows no signs of cancer having spread
People who are scheduled to have their prostate removed using a keyhole or robot-assisted surgical procedure
People who have given written consent to take part

Who may not be able to join:

People who have been rated as having very high anaesthetic risk (classified as ASA grade higher than 3) by their medical team
People for whom lymph node removal surgery is not medically suitable
People who have received hormone therapy before surgery (known as neoadjuvant hormone deprivation therapy)
People who have not given consent, or who have withdrawn their consent to participate
People whose pre-surgery PSMA PET/CT scan shows evidence that the cancer has already spread

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 6 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

The Netherlands Cancer Institute

Registry

ClinicalTrials.gov

Start date

17 November 2021

Est. completion

1 November 2024

Where this trial is recruiting

🇳🇱 Netherlands

Primary endpoints

Persistent PSA rate

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 6 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov